Grogan Donna Roy Purchases 62,000 Shares of CCCC
Grogan Donna Roy acquired 62,000 shares of CCCC, reflecting insider confidence.
Key Points
- Grogan Donna Roy purchased 62,000 shares of CCCC on June 24, 2026, signaling insider confidence.
- Shares of CCCC traded near $4.40 on Saturday, with analysts maintaining a 'buy' rating.
- Morgan Stanley increased its CCCC stake by 90,738 shares, while Vanguard Capital Management opened a new position.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Grogan Donna Roy recently bought 62,000 shares of CCCC. This insider transaction took place on June 24, 2026, indicating a level of confidence in the company. The stock traded near $4.40 on Saturday, reflecting the market's current valuation.
Other Institutional Activity in CCCC
Morgan Stanley grew its holdings in CCCC by 90,738 shares, bringing its total to 9,072,400 shares valued at approximately $23.86 million. RA Capital Management, L.P. maintained its position at 8,000,000 shares worth $21.04 million. Bain Capital Life Sciences Investors, LLC also held steady at 7,171,910 shares, valued at $18.86 million. Lynx1 Capital Management LP reduced its stake by 99,231 shares, now holding 6,998,902 shares valued at $18.41 million. Meanwhile, Vanguard Capital Management LLC opened a new position with 3,861,852 shares, valued at about $10.16 million.
C4 Therapeutics, Inc. Stock Up 14.3%
Shares of CCCC traded near $4.40 on Saturday. Although specific data on market cap, P/E ratio, and beta were not provided, the stock's recent activity and insider purchases suggest ongoing interest and potential volatility.
$CCCC stock price
Daily closing prices, year to date. Not investment advice.
Insider Buying and Selling at C4 Therapeutics, Inc.
Several insiders, including Donna Roy Grogan, Laura Bessen, and Stephen Fawell, each purchased 62,000 shares of CCCC on June 24, 2026. These transactions were not made under a Rule 10b5-1 trading plan, indicating discretionary buying. Kenneth Carl Anderson also made several transactions, including buying 1,070 shares on June 1, 2026, at $2.11 per share, and 4,259 shares on April 1, 2026, at $2.70 per share.
Analysts Set New Price Targets
On June 1, 2026, Evercore ISI Group maintained its 'buy' rating for CCCC, setting a price target of $12.0. Barclays has consistently maintained a 'buy' rating as well, with varying targets, the most recent being $7.0 on February 27, 2026. The general consensus among analysts remains positive, with a 'buy' recommendation and an average price target reflecting optimism.
Bottom Line
Grogan Donna Roy's purchase of 62,000 shares of CCCC highlights ongoing insider confidence in the company. This activity is important for investors tracking insider moves, as it can indicate potential future performance. Remember, these insider transactions are disclosed after they occur, providing a historical snapshot rather than a current recommendation.
Get C4 Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $CCCC, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.